Shield — A Blood Test for Colorectal Cancer Screening

The FDA has approved Shield (Guardant), a DNA blood test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Shield is the second blood-based DNA test to be approved for CRC screening; ColoHealth (formerly Epi proColon) was approved in 2016.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2025-06-09
DOI
https://doi.org/10.58347/tml.2025.1730b
Primary Topic
Colorectal Cancer Screening and Detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Shield — A Blood Test for Colorectal Cancer Screening

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Colorectal Cancer Screening and Detection
article

Shield — A Blood Test for Colorectal Cancer Screening

article en

Abstract

The FDA has approved Shield (Guardant), a DNA blood test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Shield is the second blood-based DNA test to be approved for CRC screening; ColoHealth (formerly Epi proColon) was approved in 2016.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 67(1730)
Good health and well-being
Openalex Percentile: Top 80%
Colorectal Cancer Screening and Detection
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Shield — A Blood Test for Colorectal Cancer Screening · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2025) | TGRS Research Map | TGRS